PHF13 is a molecular reader and transcriptional co-regulator of H3K4me2/3

  1. Chung Ho-Ryun
  2. Chao Xu
  3. Alisa Fuchs
  4. Andreas Mund
  5. Martin Lange
  6. Hannah Staege
  7. Tobias Schubert
  8. Chuanbing Bian
  9. Ilona Dunkel
  10. Anton Eberharter
  11. Catherine Regnard
  12. Henrike Klinker
  13. David Meierhofer
  14. Luca Cozzuto
  15. Andreas Winterpacht
  16. Luciano DiCroce
  17. Jinrong Min
  18. Hans Will
  19. Sarah Kinkley  Is a corresponding author
  1. Max Planck Institute for Molecular Genetics, Germany
  2. Structural Genomics Consortium, Canada
  3. Heinrich-Pette-Institute - Leibniz Institute for Experimental Virology, Germany
  4. Bayer Pharma AG, Germany
  5. Ludwig-Maximilians-University, Germany
  6. Centre for Genomic Regulation, Spain
  7. Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany

Abstract

PHF13 is a chromatin affiliated protein with a functional role in differentiation, cell division, DNA damage response and higher chromatin order. To gain insight into PHF13's ability to modulate these processes, we elucidate the mechanisms targeting PHF13 to chromatin, its genome wide localization and its molecular chromatin context. Size exclusion chromatography, mass spectrometry, X-ray crystallography and ChIP sequencing demonstrate that PHF13 binds chromatin in a multivalent fashion via direct interactions with H3K4me2/3 and DNA, and indirectly via interactions with PRC2 and RNA PolII. Furthermore, PHF13 depletion disrupted the interactions between PRC2, RNA PolII S5P, H3K4me3 and H3K27me3 and resulted in the up and down regulation of genes functionally enriched in transcriptional regulation, DNA binding, cell cycle, differentiation and chromatin organization. Together our findings argue that PHF13 is an H3K4me2/3 molecular reader and transcriptional co-regulator, affording it the ability to impact different chromatin processes.

Article and author information

Author details

  1. Chung Ho-Ryun

    Max Planck Institute for Molecular Genetics, Berlin, Germany
    Competing interests
    The authors declare that no competing interests exist.
  2. Chao Xu

    Structural Genomics Consortium, Toronto, Canada
    Competing interests
    The authors declare that no competing interests exist.
  3. Alisa Fuchs

    Max Planck Institute for Molecular Genetics, Berlin, Germany
    Competing interests
    The authors declare that no competing interests exist.
  4. Andreas Mund

    Heinrich-Pette-Institute - Leibniz Institute for Experimental Virology, Hamburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  5. Martin Lange

    TRG-ONCI, Bayer Pharma AG, Berlin, Germany
    Competing interests
    The authors declare that no competing interests exist.
  6. Hannah Staege

    Heinrich-Pette-Institute - Leibniz Institute for Experimental Virology, Hamburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  7. Tobias Schubert

    Heinrich-Pette-Institute - Leibniz Institute for Experimental Virology, Hamburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  8. Chuanbing Bian

    Structural Genomics Consortium, Toronto, Canada
    Competing interests
    The authors declare that no competing interests exist.
  9. Ilona Dunkel

    Max Planck Institute for Molecular Genetics, Berlin, Germany
    Competing interests
    The authors declare that no competing interests exist.
  10. Anton Eberharter

    Adolf-Butenandt-Institute and Center for Integrated Protein Science, Ludwig-Maximilians-University, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
  11. Catherine Regnard

    Adolf-Butenandt-Institute and Center for Integrated Protein Science, Ludwig-Maximilians-University, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
  12. Henrike Klinker

    Adolf-Butenandt-Institute and Center for Integrated Protein Science, Ludwig-Maximilians-University, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
  13. David Meierhofer

    Max Planck Institute for Molecular Genetics, Berlin, Germany
    Competing interests
    The authors declare that no competing interests exist.
  14. Luca Cozzuto

    Centre for Genomic Regulation, Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  15. Andreas Winterpacht

    Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
    Competing interests
    The authors declare that no competing interests exist.
  16. Luciano DiCroce

    Centre for Genomic Regulation, Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  17. Jinrong Min

    Structural Genomics Consortium, Toronto, Canada
    Competing interests
    The authors declare that no competing interests exist.
  18. Hans Will

    Heinrich-Pette-Institute - Leibniz Institute for Experimental Virology, Hamburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  19. Sarah Kinkley

    Max Planck Institute for Molecular Genetics, Berlin, Germany
    For correspondence
    kinkley@molgen.mpg.de
    Competing interests
    The authors declare that no competing interests exist.

Copyright

© 2016, Ho-Ryun et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,600
    views
  • 681
    downloads
  • 23
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Chung Ho-Ryun
  2. Chao Xu
  3. Alisa Fuchs
  4. Andreas Mund
  5. Martin Lange
  6. Hannah Staege
  7. Tobias Schubert
  8. Chuanbing Bian
  9. Ilona Dunkel
  10. Anton Eberharter
  11. Catherine Regnard
  12. Henrike Klinker
  13. David Meierhofer
  14. Luca Cozzuto
  15. Andreas Winterpacht
  16. Luciano DiCroce
  17. Jinrong Min
  18. Hans Will
  19. Sarah Kinkley
(2016)
PHF13 is a molecular reader and transcriptional co-regulator of H3K4me2/3
eLife 5:e10607.
https://doi.org/10.7554/eLife.10607

Share this article

https://doi.org/10.7554/eLife.10607

Further reading

    1. Chromosomes and Gene Expression
    2. Structural Biology and Molecular Biophysics
    Liza Dahal, Thomas GW Graham ... Xavier Darzacq
    Research Article

    Type II nuclear receptors (T2NRs) require heterodimerization with a common partner, the retinoid X receptor (RXR), to bind cognate DNA recognition sites in chromatin. Based on previous biochemical and overexpression studies, binding of T2NRs to chromatin is proposed to be regulated by competition for a limiting pool of the core RXR subunit. However, this mechanism has not yet been tested for endogenous proteins in live cells. Using single-molecule tracking (SMT) and proximity-assisted photoactivation (PAPA), we monitored interactions between endogenously tagged RXR and retinoic acid receptor (RAR) in live cells. Unexpectedly, we find that higher expression of RAR, but not RXR, increases heterodimerization and chromatin binding in U2OS cells. This surprising finding indicates the limiting factor is not RXR but likely its cadre of obligate dimer binding partners. SMT and PAPA thus provide a direct way to probe which components are functionally limiting within a complex TF interaction network providing new insights into mechanisms of gene regulation in vivo with implications for drug development targeting nuclear receptors.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Angel D'Oliviera, Xuhang Dai ... Jeffrey S Mugridge
    Research Article

    The SARS-CoV-2 main protease (Mpro or Nsp5) is critical for production of viral proteins during infection and, like many viral proteases, also targets host proteins to subvert their cellular functions. Here, we show that the human tRNA methyltransferase TRMT1 is recognized and cleaved by SARS-CoV-2 Mpro. TRMT1 installs the N2,N2-dimethylguanosine (m2,2G) modification on mammalian tRNAs, which promotes cellular protein synthesis and redox homeostasis. We find that Mpro can cleave endogenous TRMT1 in human cell lysate, resulting in removal of the TRMT1 zinc finger domain. Evolutionary analysis shows the TRMT1 cleavage site is highly conserved in mammals, except in Muroidea, where TRMT1 is likely resistant to cleavage. TRMT1 proteolysis results in reduced tRNA binding and elimination of tRNA methyltransferase activity. We also determined the structure of an Mpro-TRMT1 peptide complex that shows how TRMT1 engages the Mpro active site in an uncommon substrate binding conformation. Finally, enzymology and molecular dynamics simulations indicate that kinetic discrimination occurs during a later step of Mpro-mediated proteolysis following substrate binding. Together, these data provide new insights into substrate recognition by SARS-CoV-2 Mpro that could help guide future antiviral therapeutic development and show how proteolysis of TRMT1 during SARS-CoV-2 infection impairs both TRMT1 tRNA binding and tRNA modification activity to disrupt host translation and potentially impact COVID-19 pathogenesis or phenotypes.